1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zhejiang Hisoar Pharmaceutical Co., Ltd.

Zhejiang Hisoar Pharmaceutical Co., Ltd.

002099.SZ
Zhejiang Hisoar Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
5.26
CNY
-0.16
- -
8.51BMarket Cap
Zhejiang Hisoar Pharmaceutical Co., Ltd.
002099.SZ
(Shenzhen Stock Exchange)

Recent

price

5.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.66
2.04
1.76
1.77
1.73
1.72
1.62
1.48
1.71
1.83
1.55
1.57
1.54
1.34
1.23
1.23
1.98
Revenue per Share
0.13
0.17
0.04
-0.12
0.07
0.36
0.15
0.22
0.38
0.48
0.2
0.06
0.05
-0.26
-0.21
-0.06
-0.38
Basic EPS, GAAP
0.05
-0.2
-0.38
-0.34
0.03
0.12
0.34
-0.02
0.34
0.28
0.29
-0.08
-0.04
0.05
0.03
-0.09
-0.14
Free Cash Flow per Basic Share
0.04
0.08
0.12
0.08
0.07
0.12
0.13
0.07
0.13
0.3
0.3
0.03
0.11
0.07
0.02
0.02
0.03
Dividend per Share
0.57
0.69
0.88
0.75
1.22
0.92
1.49
1.62
1.79
1.96
1.87
1.91
1.67
1.51
1.33
1.33
2.28
Book Value per Share
0.91
1.06
0.97
0.85
2.63
1.65
2.39
2.47
2.57
2.76
2.86
3.07
2.75
2.77
2.68
2.72
4.59
Tangible Book Value per Share
646
637
651
657
765
1,435
1,500
1,556
1,592
1,606
1,599
1,587
1,760
1,616
1,573
1,518
923
Basic Weighted Avg Shares
1,075
1,298
1,145
1,161
1,319
2,464
2,434
2,309
2,719
2,941
2,471
2,485
2,704
2,172
1,938
1,861
1,825
Sales/Revenue/Turnover
11.69
10.72
3.53
-0.39
9.39
25.04
20.97
22.13
25.08
30.94
18.78
6.23
5.56
-7.66
2.07
-0.61
0.22
Operating Margin (%)
49
54
61
83
118
181
198
181
192
203
257
294
337
365
343
341
- -
Depreciation Expense
86
105
23
-82
54
517
225
342
605
771
320
95
88
-420
-330
-91
-354
Net Income, GAAP
14.42
18
17.78
- -
31.58
18.38
32.91
14.38
13.24
15.53
18.76
23.71
14.61
- -
- -
- -
69.65
Effective Tax Rate (%)
7.97
8.09
1.99
-7.07
4.06
20.96
9.25
14.82
22.25
26.2
12.94
3.83
3.25
-19.34
-17.04
-4.89
-19.41
Profit Margin (%)
230
312
186
-67
473
859
2,295
2,351
2,155
2,122
2,052
1,704
1,275
819
662
617
802
Working Capital
78
160
485
478
70
188
200
100
- -
- -
22
18
162
10
7
1
4
LT Debt
638
737
738
633
3,179
3,573
4,770
5,142
5,391
5,724
5,852
6,114
6,105
5,602
5,132
5,031
5,144
Total Equity
13.08
11.34
2.54
- -
3.25
12.58
6.77
7.11
9.37
12.84
6.16
1.82
1.86
- -
- -
- -
- -
Return on Invested Capital (%)
16.3
15.97
4.5
- -
7.35
31.57
9.79
10.87
17.22
22.92
9.7
3.21
3.2
- -
- -
- -
-3.46
Return on Capital (%)
25.3
25.96
4.49
-15.37
7.5
45.78
12.63
14.38
22.53
25.71
10.44
3.17
2.94
-15.61
-14.58
-4.43
-15.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,227
1,522
1,591
LT Borrowings
- -
- -
- -
LT Finance Leases
7
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,619
1,619
1,619
Market Capitalization
8,409
4,633
5,076

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,891
3,124
3,241
Cash, Cash Equivalents & STI
1,562
1,762
1,811
Accounts Receivable, Net
419
458
420
Inventories
800
796
887
Total Current Liabilities
2,228
2,362
2,438
Payables & Accruals
- -
- -
- -
ST Debt
1,227
1,522
1,591
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.03%
-2.85%
-1.97%
Free Cash Flow
-256.18%
-162.02%
-354.41%
Net Income, GAAP
-70.75%
-149.77%
-72.42%
Sales/Revenue/Turnover
-2.15%
-5.01%
-4.01%
Total Cash Common Dividend
25.59%
11%
-6.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
510
406
494
1,938
2025
486
439
494
- -
1,861
2026
486
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
-0.21
2025
0.01
- -
- -
- -
-0.06
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.02
2025
0.01
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Fiore Cannabis Ltd. (FIOR.CN)
CENTR Brands Corp. (CNTR.CN)
Henan Taloph Pharmaceutical Stock Co.,Ltd (600222.SS)
The Valens Company Inc. (VLNS)
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ)
Clever Leaves Holdings Inc. (CLVRW)
Business
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) engages in the research, development, production and sale of active pharmaceutical ingredients, pharmaceutical intermediates, generic formulations, fine chemicals, dyestuffs and dye intermediates. The company manufactures antibiotics including clindamycin series and meropenem, cardiovascular drugs such as metoprolol succinate, hypoglycemic agents like repaglinide and voglibose, anti-inflammatory agents, anti-HIV medications, anti-diabetic products and related intermediates; it also produces environmentally friendly reactive dyes such as active brilliant blue KN-R series with global market share exceeding 60%, anthraquinone dyes and pigment intermediates, alongside contract manufacturing services (CMO/CDMO) for multinational pharmaceutical companies. Over 70% of pharmaceutical products export internationally, with leading global positions in clindamycin production; operations span China with production bases in Taizhou, Yichang and Jiangsu, plus overseas entities including Genevida GmbH in Germany and Hong Kong holdings. Founded in 1966 and headquartered at No. 100 Waishazhi Road, Jiaojiang District, Taizhou, Zhejiang Province, China, the company operates as a listed entity controlled by Dankong Industry & Trade Group Co., Ltd. following its 2014 acquisition, with subsidiaries including Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd., Taizhou Qianjin Chemical Co., Ltd. and Zhejiang Qilian Environmental Protection Technology Co., Ltd. It maintains a national enterprise technology center, postdoctoral workstation and provincial research institutes focused on Haixiang Pharmaceutical and Taizhou Qianjin. Recent developments include the completion of a share repurchase program announced April 2025, acquiring 4.41 million shares or 0.28% of outstanding shares for CNY 25.59 million by September 2025; establishment of Yichang Hisoar Pharmaceutical Co., Ltd. in planning stages; and in 2020 launch of a mask production line alongside COVID-19 donations, plus formation of Zhejiang Qilian for hazardous waste management.